CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
Cetuximab and Lenalidomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01133665
NCT01133665Phase 2Completed
CompareCT.gov

Phase II Study of Cetuximab and Lenalidomide in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

University of Chicago·interventional·Posted May 31, 2010·Updated Nov 24, 2014

In Brief

A Phase 2 clinical trial evaluating Cetuximab and Lenalidomide for Squamous Cell Carcinoma. Completed, enrolled 42 participants across 1 site.

Detailed Summary

The purpose of this study is to study specific FcRIIIa polymorphisms and their correlation with clinical outcome in subjects treated with cetuximab and lenalidomide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinoma
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 31, 2010
Enrollment StartFeb 1, 2010
Primary CompletionAug 1, 2011
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.1 years ago

Interventions

Cetuximab and Lenalidomidedrug

The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide